Founded in 2006, ImmuneWorks is a biotech company based in Indianapolis, Indiana, that develops innovative therapeutics for patients with lung diseases. The company's scientific foundation is based on its groundbreaking discovery that antigen-specific autoimmunity is responsible for the disease in over half of idiopathic pulmonary fibrosis (IPF) patients. ImmuneWorks aims to develop safe and effective immune tolerance treatments for patients with serious autoimmune diseases of the lung, using biotechnological procedures to improve their quality of life.